Hypertension (HTN)NCT07475208
NR and Exercise for Blood Pressure
A study testing Brisk walking and Nicotinamide Riboside 1000 mg in people with Hypertension (HTN), run by ZHANG Jiaqi.
Trial summary
Hypertension continues to pose a significant global health challenge, with rates of optimal blood pressure control remaining low - particularly in China, where fewer than 5% of individuals with hypertension achieve guideline-recommended targets. Read more about this study
- Who is it for?
- Ages 55 to 80 years, women only
- Conditions the study is for
- Hypertension (HTN)
- What is being tested?
- Brisk walking and Nicotinamide Riboside 1000 mg
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 112 participants
- Where
- No sites listed yet
- Study dates
- Apr 2026to Dec 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 55 to 80 years
- Women only
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- women absent of menstruation for over one year,
- Chinese, and
- fulfill the criteria of elevated/stage I hypertension according to 2025 American College of Cardiology/American Heart Association Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (i.e., blood pressure ≥120/80 mmHg based on an average of ≥2 readings obtained on ≥2 occasions)
Who cannot join
- presence of health conditions that contraindicate participation in exercise training, such as a history of cardiovascular disease, cancer, or musculoskeletal disorders,
- a history of hysterectomy,
- current use of vitamin B supplements and/or NAD precursors,
- ongoing hormone replacement therapy within the past six months,
- any changes in antihypertensive medication type or dosage within the last three months, or
- engagement in regular physical activity, defined as at least 150 minutes of moderate-intensity exercise or 75 minutes of vigorous-intensity exercise per week, during the three months prior to enrollment.
About this study
Official title: Effects of Ten-Week Oral Nicotinamide Riboside Supplementation With Aerobic Exercises on Blood Pressure in Post- Menopausal Women With Elevated/Stage I Hypertension
Hypertension continues to pose a significant global health challenge, with rates of optimal blood pressure control remaining low - particularly in China, where fewer than 5% of individuals with hypertension achieve guideline-recommended targets.
Age-associated endothelial dysfunction and arterial stiffness are recognized as the key contributors to the development of hypertension and the unique role of nicotinamide adenine dinucleotide (NAD) depletion in the pathogenesis of vascular dysfunction has been recently discovered. Treatment with nicotinamide riboside (NR), an NAD precursor, has shown promise in preliminary clinical trials for improving blood pressure and vascular health in at-risk populations.
Read more
In parallel, aerobic exercise is a well-established non-pharmacologic intervention known to improve cardiovascular outcomes. Emerging studies suggest that exercise may modulate NAD biosynthesis pathways, pointing toward a synergistic potential when combined with NAD-boosting strategies. However, clinical data evaluating the combined effects of NR supplementation and aerobic exercise remain scarce.
Our randomized, placebo-controlled, four-arm, parallel-group design seeks to address this gap. The investigators will investigate the independent and combined effects of 10-week NR supplementation and brisk walking on blood pressure and vascular health in post-menopausal women with elevated/stage I hypertension. This population is specifically targeted due to their heightened risk for vascular dysfunction post-menopause and the observed responsiveness to NR-based interventions in prior studies.
The investigators believe the findings from this trial will provide insight into the feasibility, safety, and efficacy of combining NAD-boosting supplementation with structured exercise in a uniquely vulnerable and previously understudied population. The potential to identify a low-risk, non-pharmaceutical therapeutic approach holds strong implications for public health, particularly in aging women with early-stage hypertension.
- Conditions
- Hypertension (HTN)
- Being tested
- Brisk walking, Nicotinamide Riboside 1000 mg, Placebo
- Medical subject headings
- Hypertension
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Brisk walkingBehavioural
Brisk walking twice per week
Nicotinamide Riboside 1000 mgDietary supplement
Nicotinamide Riboside supplementation 1000 mg per day
PlaceboOther
Placebo
| Study group | Role | What they receive |
|---|---|---|
| NR + BW | Experimental | NR supplementation plus brisk walking Receives: Behavioral: Brisk walking; Dietary Supplement: Nicotinamide Riboside 1000 mg |
| PL + BW | Placebo comparator | Placebo plus brisk walking Receives: Behavioral: Brisk walking; Other: Placebo |
| NR | Active comparator | NR supplementation only Receives: Dietary Supplement: Nicotinamide Riboside 1000 mg |
| PL | Placebo comparator | Placebo only Receives: Other: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Blood pressure
Blood pressure will be measured using an automated sphygmomanometer that meets the standards from the Association for the Advancement of Medical Instrumentation and the European Society for Hypertension and following standardized procedures. Two measurements will be taken after 5 min sitting rest in a quiet room with comfortable temperature. During assessments, participants will be seated with their back supported, feet flat on the floor, legs uncrossed, and their arm resting on a table with the midpoint of the upper arm aligned at heart level. Two readings of systolic and diastolic blood pressures will be obtained, spaced 2 minutes apart, and the average of the two measurements will be recorded as the final blood pressure reading. If the difference between the two measurements exceeds 5 mmHg, an additional reading will be taken, and the average of all three readings will be used as the final measurement.
Measured: From enrollment to the end of follow-up at 20 weeks
Secondary outcomes (13)
Whole Blood NAD concentration
Whole blood NAD concentration will be analyzed with commercially available colorimetric assay kit according to manufacturer's instructions using thawed whole blood samples.
Measured: From enrollment to the end of follow-up at 20 weeks
Endothelin 1
ET-1 will be analyzed with commercially available ELISA kit according to manufacturer's instructions using thawed serum samples and will serve as indicators of vascular function.
Measured: From enrollment to the end of follow-up at 20 weeks
Angiotensin
Angiotensin will be analyzed with commercially available ELISA kit according to manufacturer's instructions using thawed serum samples and will serve as indicators of vascular function.
Measured: From enrollment to the end of follow-up at 20 weeks
Body mass
Measured with bioelectrical impedance analysis (BIA) (MC-780 MA, Tanita, Japan) with participants in minimum clothing and normal hydration status.
Measured: From enrollment to the end of follow-up at 20 weeks
Fat mass
Measured with bioelectrical impedance analysis (BIA) (MC-780 MA, Tanita, Japan) with participants in minimum clothing and normal hydration status
Measured: From enrollment to the end of follow-up at 20 weeks
Fat-free mass
Measured with bioelectrical impedance analysis (BIA) (MC-780 MA, Tanita, Japan) with participants in minimum clothing and normal hydration status.
Measured: From enrollment to the end of follow-up at 20 weeks
Fat percentage
Measured with bioelectrical impedance analysis (BIA) (MC-780 MA, Tanita, Japan) with participants in minimum clothing and normal hydration status.
Measured: From enrollment to the end of follow-up at 20 weeks
Height
Measured using a stadiometer (Seca, Leicester, UK).
Measured: From enrollment to the end of follow-up at 20 weeks
BMI
Calculated as body mass (kg) divided by height squared (m2).
Measured: From enrollment to the end of follow-up at 20 weeks
Waist Circumference
Measured using anthropometric tape.
Measured: From enrollment to the end of follow-up at 20 weeks
Seven-day accelerometry
Participants will be instructed to wear a wrist accelerometer device on their non-dominant wrists 24 hours for 7 days to measure habitual physical activity pattern. Data will be downloaded and saved in raw format, then processed and analyzed with R-package GGIR.
Measured: From enrollment to the end of follow-up at 20 weeks
30-second chair stand test
Muscle strength of the lower extremities will be assessed using the 30-second chair stand test. During the test, participants will be instructed to stand up to a full standing position and then sit back down as many times as possible within 30 seconds. The number of times participants achieve a full standing position will be recorded as their score.
Measured: From enrollment to the end of follow-up at 20 weeks
Handgrip strength
Measured using a hand-held dynamometer.
Measured: From enrollment to the end of follow-up at 20 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Mar 2026
- Study startApr 2026 (estimated)
- Primary completionDec 2026 (estimated)
- Study completionDec 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Hypertension (HTN)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Participant, Investigator, Outcomes assessor
- Enrolment
- 112 participants (estimated)
Sponsor and investigators
- Lead sponsor
- ZHANG Jiaqi
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, ZHANG Jiaqi, Chinese University of Hong Kong
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07475208
- Sponsor's protocol ID
- NTEC-2025-596
- Status last verified
- Mar 2026
- First submitted
- 12 Mar 2026
- Last updated
- 18 Mar 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 18 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effects of Ten-Week Oral Nicotinamide Riboside Supplementation With Aerobic Exercises on Blood Pressure in Post- Menopausal Women With Elevated/Stage I Hypertension
- ClinicalTrials.gov ID
- NCT07475208
- Acronym / sponsor ID
- NTEC-2025-596
- Conditions
- Hypertension (HTN)
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 112 participants (estimated)
- Lead sponsor
- ZHANG JiaqiUniversity, hospital or other
- Study start
- Apr 2026 (estimated)
- Primary completion
- Dec 2026 (estimated)
- Study completion
- Dec 2027 (estimated)
- First posted
- 16 Mar 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Hypertension continues to pose a significant global health challenge, with rates of optimal blood pressure control remaining low - particularly in China, where fewer than 5% of individuals with hypertension achieve guideline-recommended targets.
Age-associated endothelial dysfunction and arterial stiffness are recognized as the key contributors to the development of hypertension and the unique role of nicotinamide adenine dinucleotide (NAD) depletion in the pathogenesis of vascular dysfunction has been recently discovered. Treatment with nicotinamide riboside (NR), an NAD precursor, has shown promise in preliminary clinical trials for improving blood pressure and vascular health in at-risk populations.
In parallel, aerobic exercise is a well-established non-pharmacologic intervention known to improve cardiovascular outcomes. Emerging studies suggest that exercise may modulate NAD biosynthesis pathways, pointing toward a synergistic potential when combined with NAD-boosting strategies. However, clinical data evaluating the combined effects of NR supplementation and aerobic exercise remain scarce.
Our randomized, placebo-controlled, four-arm, parallel-group design seeks to address this gap. The investigators will investigate the independent and combined effects of 10-week NR supplementation and brisk walking on blood pressure and vascular health in post-menopausal women with elevated/stage I hypertension. This population is specifically targeted due to their heightened risk for vascular dysfunction post-menopause and the observed responsiveness to NR-based interventions in prior studies.
The investigators believe the findings from this trial will provide insight into the feasibility, safety, and efficacy of combining NAD-boosting supplementation with structured exercise in a uniquely vulnerable and previously understudied population. The potential to identify a low-risk, non-pharmaceutical therapeutic approach holds strong implications for public health, particularly in aging women with early-stage hypertension.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, investigator, outcomes assessor)
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| NR + BW | Experimental | Behavioral: Brisk walking, Dietary Supplement: Nicotinamide Riboside 1000 mgNR supplementation plus brisk walking |
| PL + BW | Placebo comparator | Behavioral: Brisk walking, Other: PlaceboPlacebo plus brisk walking |
| NR | Active comparator | Dietary Supplement: Nicotinamide Riboside 1000 mgNR supplementation only |
| PL | Placebo comparator | Other: PlaceboPlacebo only |
Who may qualify
- Ages
- 55 to 80 years
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- women absent of menstruation for over one year,
- Chinese, and
- fulfill the criteria of elevated/stage I hypertension according to 2025 American College of Cardiology/American Heart Association Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (i.e., blood pressure ≥120/80 mmHg based on an average of ≥2 readings obtained on ≥2 occasions)
Key exclusion criteria (6 listed)
- presence of health conditions that contraindicate participation in exercise training, such as a history of cardiovascular disease, cancer, or musculoskeletal disorders,
- a history of hysterectomy,
- current use of vitamin B supplements and/or NAD precursors,
- ongoing hormone replacement therapy within the past six months,
- any changes in antihypertensive medication type or dosage within the last three months, or
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Brisk walkingBrisk walking twice per week | Behavioural | NR + BW, PL + BW |
| Nicotinamide Riboside 1000 mgNicotinamide Riboside supplementation 1000 mg per day | Dietary supplement | NR, NR + BW |
| PlaceboPlacebo | Other | PL, PL + BW |
Primary outcome
Blood pressure
Time frame: From enrollment to the end of follow-up at 20 weeks
Blood pressure will be measured using an automated sphygmomanometer that meets the standards from the Association for the Advancement of Medical Instrumentation and the European Society for Hypertension and following standardized procedures. Two measurements will be taken after 5 min sitting rest in a quiet room with comfortable temperature. During assessments, participants will be seated with their back supported, feet flat on the floor, legs uncrossed, and their arm resting on a table with the midpoint of the upper arm aligned at heart level. Two readings of systolic and diastolic blood pressures will be obtained, spaced 2 minutes apart, and the average of the two measurements will be recorded as the final blood pressure reading. If the difference between the two measurements exceeds 5 mmHg, an additional reading will be taken, and the average of all three readings will be used as the final measurement.
13 secondary outcomes
Whole Blood NAD concentration
Time frame: From enrollment to the end of follow-up at 20 weeks
Endothelin 1
Time frame: From enrollment to the end of follow-up at 20 weeks
Angiotensin
Time frame: From enrollment to the end of follow-up at 20 weeks
Body mass
Time frame: From enrollment to the end of follow-up at 20 weeks
Fat mass
Time frame: From enrollment to the end of follow-up at 20 weeks
Fat-free mass
Time frame: From enrollment to the end of follow-up at 20 weeks
Fat percentage
Time frame: From enrollment to the end of follow-up at 20 weeks
Height
Time frame: From enrollment to the end of follow-up at 20 weeks
BMI
Time frame: From enrollment to the end of follow-up at 20 weeks
Waist Circumference
Time frame: From enrollment to the end of follow-up at 20 weeks
Seven-day accelerometry
Time frame: From enrollment to the end of follow-up at 20 weeks
30-second chair stand test
Time frame: From enrollment to the end of follow-up at 20 weeks
Handgrip strength
Time frame: From enrollment to the end of follow-up at 20 weeks
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Mar 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Hypertension (HTN)
RecruitingPhase 4
Initial Triple Therapy Including Parenteral Treprostinil vs Initial Double Oral Therapy in PAH Group I Patients
Pulmonary Arterial Hypertension
Not yet recruiting
Effects of Smartphone Use and Television Viewing on Standardized BP Measurement: The SCREENS-BP Study
Hypertension
Not yet recruiting
Care COMPASS Study
Diabetes Mellitus ( Type 1 and Type 2), Hypertension
RecruitingPhase 4
De-implementing Inhaled Nitric Oxide for Congenital Diaphragmatic Hernia
Congenital Diaphragmatic Hernia
RecruitingPhase 2
Spironolactone for Pulmonary Arterial Hypertension
Pulmonary Arterial Hypertension
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
A study testing Brisk walking and Nicotinamide Riboside 1000 mg in people with Hypertension (HTN), run by ZHANG Jiaqi.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 18 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Blood pressure (time frame: From enrollment to the end of follow-up at 20 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Mar 2026.